PAPILLARY MICROCARCINOMA IN COMPARISON WITH LARGER PAPILLARY THYROID CARCINOMA IN BRAF(V600E) MUTATION, CLINICOPATHOLOGICAL FEATURES, AND IMMUNOHISTOCHEMICAL FINDINGS

Background. Papillary thyroid microcarcinoma (PMC; 1 cm. Results. The prevalence of extrathyroidal invasion (52.2%) and initial nodal metastasis (34.9%) in patients with PMC was surprisingly high and almost as high as that for patients with PTC (72.4% and 51.8%, respectively). The rate of recurrent or persistent disease did not differ between patients with PMC and PTC (recurrent or persistent disease, 6.1% vs 14.1%: 53.4- vs 84.2-month follow-up; n = 98 vs 647; corrected P = .112). The frequency of BRAF(V600E) mutation was similar in patients with PMC and PTC (65.6% vs 67.2%). Immunohistochemical staining showed no different expression pattern according to the tumor size. Conclusion. These results suggest that PMC is not an occult cancer and it can act like larger PTC. Therefore, PMC should not be underestimated in practice. (C) 2009 Wiley Periodicals, Inc. Head Neck 32: 38-45, 2010Lupi C, 2007, J CLIN ENDOCR METAB, V92, P4085, DOI 10.1210/jc.2007-1179Rodolico V, 2007, CANCER, V110, P1218, DOI 10.1002/cncr22912Lee JH, 2007, CANCER, V110, P38, DOI 10.1002/cncr.22754Hay ID, 2006, J SURG ONCOL, V94, P692, DOI 10.1002/jso.20696Roti E, 2006, J CLIN ENDOCR METAB, V91, P2171, DOI 10.1210/jc.2005-2372Lo CY, 2006, WORLD J SURG, V30, P759, DOI 10.1007/s00268-005-0363-8Chen YK, 2005, ANTICANCER RES, V25, P1421Kovacs GL, 2005, THYROID, V15, P152Prasad ML, 2005, MODERN PATHOL, V18, P48, DOI 10.1038/modpathol.3800235Ito Y, 2005, ANTICANCER RES, V25, P179Sedliarou I, 2004, INT J ONCOL, V25, P1729Ito Y, 2004, WORLD J SURG, V28, P1115, DOI 10.1007/s00268-004-7644-5Bojunga J, 2004, CLIN ENDOCRINOL, V61, P523, DOI 10.1111/j.1365-2265.2004.02131.xKim KH, 2004, YONSEI MED J, V45, P818Pellegriti G, 2004, J CLIN ENDOCR METAB, V89, P3713, DOI 10.1210/jc.2003-031982Pearce EN, 2004, J CLIN ENDOCR METAB, V89, P3710, DOI 10.1210/jc.2004-1189Pelizzo MR, 2004, NUCL MED COMMUN, V25, P547, DOI 10.1097/01.mnm.0000126625.17166.36Silver RJ, 2004, SURG CLIN N AM, V84, P907, DOI 10.1016/j.suc.2004.02.002Nam-Goong IS, 2004, CLIN ENDOCRINOL, V60, P21, DOI 10.1046/j.1365-2265.2003.01912.xNikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838Namba H, 2003, J CLIN ENDOCR METAB, V88, P4393, DOI 10.1210/jc.2003-030305Chow SM, 2003, CLIN ONCOL-UK, V15, P329, DOI 10.1016/S0936-6555(03)00066-9Xu XL, 2003, CANCER RES, V63, P4561Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706Chow SM, 2003, CANCER, V98, P31, DOI 10.1002/cncr.11442Kimura ET, 2003, CANCER RES, V63, P1454Ito Y, 2003, THYROID, V13, P381COHEN Y, 2003, J NATL CANCER I, V95, P625Appetecchia M, 2002, J EXP CLIN CANC RES, V21, P159Papini E, 2002, J CLIN ENDOCR METAB, V87, P1941Khoo MLC, 2002, J CLIN ENDOCR METAB, V87, P1814Timler D, 2001, FOLIA HISTOCHEM CYTO, V39, P201Wang S, 2000, MODERN PATHOL, V13, P882Nasir A, 2000, IN VIVO, V14, P367Liberman E, 2000, APPL IMMUNOHISTO M M, V8, P42Baudin E, 1998, CANCER, V83, P553Resnick MB, 1998, MODERN PATHOL, V11, P735Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737HAY ID, 1992, SURGERY, V112, P1139HAY ID, 1992, SURGERY, V112, P1146YAMAMOTO Y, 1990, CANCER, V65, P1173SCHELFHOUT LJDM, 1989, AM J CLIN PATHOL, V92, P654HARACH HR, 1985, CANCER, V56, P531BONDESON L, 1981, CANCER, V47, P319